Public advisory

All lots of JAMP-Clopidogrel 75 mg and AG-Clopidogrel 75 mg tablets recalled due to possible incorrect dose, which may pose health risks

Last updated

Summary

Product
JAMP-Clopidogrel 75 mg and AG-Clopidogrel 75 mg tablets
Issue
Health products - Product safety
Health products - Dosage
What to do

If you are taking the affected products, speak with your pharmacist as soon as possible. Continue to take your JAMP-Clopidogrel 75 mg or AG-Clopidogrel 75 mg tablets until you speak with your pharmacist and get a replacement product. Contact a health care professional immediately if you or someone you are caring for experiences serious side effects due to an incorrect dose of clopidogrel.

Affected products

Product DIN Lot Expiry
JAMP-Clopidogrel 75 mg tablets 02415550 EG22CGM002

EG22CGM003

EG22CGN001

EG23CGN001

EG23CGN002

EG23CGN003

EG23CGM001

EG23CGL001

EG23CGN004
2025-09-30

2025-09-30

2025-09-30

2026-05-31

2026-07-31

2026-07-31

2026-07-31

2026-07-31

2026-07-31
AG-Clopidogrel 75 mg tablets 02431971 EG23AGH001

EG23AGM001
2026-07-31

2026-07-31

Issue

JAMP Pharma Corporation and Angita (AG) Pharma Inc. are recalling all lots of JAMP-Clopidogrel and AG-Clopidogrel 75 mg tablets as some tablets may weigh less or more than they should, meaning patients could unexpectedly receive a lower or higher dose than intended. There may be serious risks associated with the use of an incorrect dose of clopidogrel. Patients taking the affected product should return it to the pharmacy as soon as possible but should not stop their medication until they get a replacement product.

Clopidogrel, a prescription drug, is used in adults to help prevent blood clots and reduce the risk of having conditions caused by blood clots such as strokes, unstable angina (chest pain at rest), heart attacks, or peripheral arterial disease (leg pain while walking or at rest) and other circulation problems. It may also be used in adults who have atrial fibrillation (irregular heartbeat).

Taking a lower dose than intended can reduce the drug’s effectiveness and may lead to an increased risk of stroke, heart attack, and other serious blood vessel problems.

Taking a higher dose than intended can result in an overdose. Signs and symptoms of a clopidogrel overdose may include prolonged bleeding time and subsequent bleeding complications (e.g., nose bleeds, blood in the stool, urine, or eye, vomiting blood, coughing up blood, or a purple spotted rash). Worsening of other side effects such as nausea, vomiting, loss of taste, diarrhea, dizziness, headache, rash, bruising, and joint and/or muscle pain may also occur.

Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventative actions to stop this issue from reoccurring. The Department will inform the public if any new health risks are identified.

What you should do

  • If you are taking the affected products, speak with your pharmacist as soon as possible. It may not be possible to know if you are getting the correct dose of clopidogrel by looking at the tablets since overweight or underweight tablets may look like normal-sized tablets.
  • Continue taking your JAMP-Clopidogrel 75 mg or AG-Clopidogrel 75 mg tablets until you speak with your pharmacist and get a replacement product.
  • Contact a health care professional immediately if you or someone you are caring for experiences serious side effects related to an incorrect dose of clopidogrel.
  • If you have questions about this recall, contact JAMP Pharma Corporation by calling toll-free at 1-866-399-9091, extension 501, or by email at custjamp@jamppharma.com, or Angita Pharma Inc. at 450-449-9272 or by email at custangita@angitapharma.ca.
  • Report any health product-related side effects or complaints to Health Canada.

Additional information

Details
Original published date:
Alert / recall type
Public advisory
Category
Health products - Drugs
Companies
Published by
Health Canada
Audience
General public
Identification number
RA-76003
Media and public enquiries

Media Enquiries:

Health Canada

(613) 957-2983

media@hc-sc.gc.ca

Public Enquiries:

(613) 957-2991

1-866 225-0709

info@hc-sc.gc.ca

Get notified

Receive notifications for new and updated recalls and alerts by category.

Subscribe